Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of “Hold” by Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $10.50.

AGEN has been the topic of a number of analyst reports. B. Riley lowered their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Baird R W lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. William Blair lowered shares of Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $7.00 price objective (up previously from $3.00) on shares of Agenus in a research note on Friday, July 19th.

Institutional Investors Weigh In On Agenus

Large investors have recently modified their holdings of the stock. Point72 DIFC Ltd purchased a new stake in shares of Agenus during the 2nd quarter worth approximately $51,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Agenus during the 2nd quarter worth approximately $106,000. Blair William & Co. IL purchased a new stake in shares of Agenus during the 2nd quarter worth approximately $441,000. Squarepoint Ops LLC purchased a new stake in shares of Agenus during the 2nd quarter worth approximately $614,000. Finally, Ovata Capital Management Ltd purchased a new stake in shares of Agenus during the 2nd quarter worth approximately $670,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Price Performance

AGEN stock opened at $4.55 on Wednesday. Agenus has a 1 year low of $4.41 and a 1 year high of $23.20. The stock has a market capitalization of $95.55 million, a PE ratio of -0.35 and a beta of 1.37. The company’s 50-day moving average is $5.31 and its 200-day moving average is $9.66.

Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The company had revenue of $23.51 million for the quarter, compared to the consensus estimate of $64.73 million. During the same quarter in the previous year, the company earned ($4.00) EPS. On average, analysts anticipate that Agenus will post -10.87 earnings per share for the current fiscal year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.